A pivotal week for Bayer AG is set to test the company’s strategy on two continents, with a shareholder vote in Germany and a Supreme Court hearing in the United States poised to shape its multi-billion dollar legal and financial future. The convergence of these events underscores the immense pressure on CEO Bill Anderson to resolve the enduring glyphosate litigation inherited from the Monsanto acquisition.
The US Supreme Court will hear arguments on April 27, 2026, a date that coincides with Bayer’s ex-dividend day. The company is seeking to definitively halt state-level lawsuits regarding cancer warning labels for its Roundup weedkiller. Bayer’s legal position, which has received backing from the US Justice Department, argues that federal law—specifically the EPA’s approval without a cancer warning—should preempt state law. A final ruling in Bayer’s favor, expected by the end of June, could remove the legal basis for thousands of future claims.
Parallel to this judicial effort, Bayer is advancing a massive settlement package in Missouri. This deal, valued at over $7 billion, has received preliminary approval. Claimants retain the right to opt out until June 4, as the company works to establish what it hopes will be a dual safety net. Recent reports suggest a potential global settlement figure could be around $7.5 billion, as management seeks a structured path to reduce a total litigation risk analysts estimate at approximately €24 billion.
The financial toll is already severe. Bayer has set aside provisions nearing €12 billion for the legal battles. For 2026 alone, the company anticipates outflows of about €5 billion related to these matters, a drain that will push its free cash flow deeply into negative territory. In a clear signal of where cash is being prioritized, the board has proposed a nominal dividend of just €0.11 per share for the upcoming Annual General Meeting. Shareholders will vote on this payout on April 24, with payment scheduled for April 29.
Should investors sell immediately? Or is it worth buying Bayer?
Despite the staggering legal costs, Bayer’s management has reaffirmed its full-year guidance. The company expects group sales to reach up to €47 billion, asserting that neither the litigation nor new US import tariffs on pharmaceuticals jeopardize its operational targets. A key growth driver is the heart drug Kerendia, for which Bayer is targeting peak sales exceeding €3 billion.
Investors are watching closely as this critical sequence of events unfolds. The stock recently traded around €40.57, marking a gain of nearly 1.5% for the session and roughly 6.7% since the start of the year. Technical indicators show a Relative Strength Index (RSI) reading near 23, signaling the shares are in oversold territory and suggesting the market has heavily priced in the ongoing risks.
The company’s first-quarter results, due on May 12, will offer the next insight into the performance of its three divisions: Crop Science, Pharmaceuticals, and Consumer Health. They will also provide a first look at the operational impact of Bayer’s new “Dynamic Shared Ownership” organizational model, designed to accelerate decision-making. For now, the immediate course of the stock likely hinges on tangible progress toward a definitive glyphosate resolution. Without that catalyst, the share price may remain trapped within its current range.
Ad
Bayer Stock: Buy or Sell?! New Bayer Analysis from April 22 delivers the answer:
The latest Bayer figures speak for themselves: Urgent action needed for Bayer investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from April 22.
Bayer: Buy or sell? Read more here...
